semaglutide abuse Discontinuation and Its Health Implications Semaglutide: Shedding pounds, weighing risks

Efectos secundarios y consideraciones de seguridad Los medicamentos GLP-1 son generalmente bien tolerados, pero pueden causar efectos secundarios que los pacientes deben conocer antes de iniciar el tratamiento

As of April 2026, neither semaglutide nor tirzepatide appears on the FDA's drug shortage list or 503B bulks list

The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)

What reduced appetite actually feels like People often expect a dramatic switch, but the change is usually quieter than that